How Rescheduling Affects Cannabis Businesses: Trigger Rules, DEA Registration & Interstate Commerce

The DOJ's rescheduling order is historic, but what it means for your cannabis business depends largely on where you operate. The order moves state-licensed medical cannabis to Schedule III and opens a pathway for state-licensed entities to obtain federal DEA registration as manufacturers, distributors and/or dispensers. But not all states respond to federal scheduling changes the same way. Depending on your state's regulatory framework, licensing requirements, dispensing rules, pharmacy authorization models and interstate commerce rules may all look very different in the months ahead. Has your state already started changing its laws? Which states will conform quickly? If you hold a state medical license and register with the DEA, are you compliant with the Controlled Substances Act? Does rescheduling mean products can be sold across state lines? What does DEA registration actually require, and should you apply? How should compliance programs be updated and how much depends on where you operate? Topics include: The four categories of state trigger laws and what each means for operators following the DOJ order A state-by-state breakdown of how each may revise controlled substance scheduling, licensing and operational rules, including the top five medical states to watch DEA registration, the application process, the 60-day expedited window and what registration does and does not guarantee Interstate commerce, what the order's new import/export framework permits and where state law still governs Practical considerations for operators, licensees and stakeholders monitoring federal and state implementation You’ll hear from: Neil Willner, Counsel Jerrico Perez, Partner Casey Leaver, Senior Director of Regulatory Compliance Emily Hackman, Director of Licensing - California https://vicentellp.com/insights/webin...